SI9620111B - Imidazole derivatives having affinity for alpha2 receptors activity - Google Patents
Imidazole derivatives having affinity for alpha2 receptors activity Download PDFInfo
- Publication number
- SI9620111B SI9620111B SI9620111A SI9620111A SI9620111B SI 9620111 B SI9620111 B SI 9620111B SI 9620111 A SI9620111 A SI 9620111A SI 9620111 A SI9620111 A SI 9620111A SI 9620111 B SI9620111 B SI 9620111B
- Authority
- SI
- Slovenia
- Prior art keywords
- hydrogen
- alkyl
- derivative according
- derivative
- hydroxy
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title claims abstract 3
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 22
- 239000001257 hydrogen Substances 0.000 claims abstract 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 13
- 208000002193 Pain Diseases 0.000 claims abstract 6
- 150000002431 hydrogen Chemical group 0.000 claims abstract 5
- -1 C3-C7-cycloalkyl Chemical group 0.000 claims abstract 3
- 208000000094 Chronic Pain Diseases 0.000 claims abstract 3
- 206010012335 Dependence Diseases 0.000 claims abstract 3
- 206010012735 Diarrhoea Diseases 0.000 claims abstract 3
- 208000010412 Glaucoma Diseases 0.000 claims abstract 3
- 206010020772 Hypertension Diseases 0.000 claims abstract 3
- 208000019695 Migraine disease Diseases 0.000 claims abstract 3
- 208000005298 acute pain Diseases 0.000 claims abstract 3
- 230000001684 chronic effect Effects 0.000 claims abstract 3
- 208000010877 cognitive disease Diseases 0.000 claims abstract 3
- 208000028867 ischemia Diseases 0.000 claims abstract 3
- 206010027599 migraine Diseases 0.000 claims abstract 3
- 201000009240 nasopharyngitis Diseases 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims abstract 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims abstract 2
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 2
- 208000025966 Neurological disease Diseases 0.000 claims abstract 2
- 229940124534 adjunct to anesthesia Drugs 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 150000001721 carbon Chemical group 0.000 claims abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 230000000926 neurological effect Effects 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 2
- 208000020016 psychiatric disease Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000003573 thiols Chemical class 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Resins (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
IMIDAZOLOVI DERIVATI, KI IMAJO AFINITETO ZA AKTIVNOST ALFA2 RECEPTORJEV
Claims (18)
- PATENTNI ZAHTEVKI1. Derivat imidazola, ki je spojina s formulo I n je 0 ali 1R1 je vodik ali C^-C^alkilR2 je vodik, ali R2 in Rg skupaj tvorita dvojno vezRg je vodik ali C-j-C4-alkil, ali R2 in Rg skupaj tvorita dvojno vezR4 je vodik, C-j-C4-alkil, hidroksi ali C^C^alkoksiRg je vodik ali C-j-C^-alkil, ali R4 in Rg skupaj z atomom ogljika, na katerega sta vezana, tvorita karbonilno skupino.Rg, R7 in Rg so vsi enaki ali različni in so neodvisno vodik, C^-C4-alkil ali C2-C4-alkenil, Cg-Cy-cikloalkil, hidroksi, C^-C4-alkoksi, C^-C^-hidroksialkil, tiol, 4-alkiltio, 4-alkiltiol, halogen, trifluorometil, nitro ali po izbiri substituirani amino X je -CHR9-(CHRw)mm je 0 ali 1 in Rg in R^q sta oba enaka ali različna in sta neodvisno vodik ali C^-C4-alkil; ali farmacevtsko sprejemljiv ester ali sol le-teh.
- 2. Derivat v skladu z zahtevkom 1, označen s tem, da je n = m=0.
- 3. Derivat v skladu z zahtevkom 1 ali 2, označen s tem, da so Rg, Ry in Rg vsi vodik.
- 4. Derivat v skladu z zahtevkom 1 ali 2, označen s tem, da je Rg C^-C^alkil na poziciji 4 ali 6 indanovega obroča, R7 in Re pa sta vodik.
- 5. Derivat v skladu z zahtevkom 1 ali 2, označen s tem, da je R6 C,-C4-alkoksi na poziciji 7 indanovega obroča, R7 in R„ pa sta vodik.
- 6. Derivat v skladu z zahtevkom 1, označen s tem, da je n=1 in m=0.
- 7. Derivat v skladu z zahtevkom 6, označen s tem, da je R, metil ali etil.
- 8. Derivat v skladu z zahtevkom 6 ali 7, označen s tem, da so R6, R7 in R8 vsi vodik.
- 9. Derivat v skladu z zahtevkom 6 ali 7, označen s tem, da je R6 hidroksi na poziciji 4 aii 6 indanovega obroča, R7 in Re pa sta vodik.
- 10. Derivat v skladu z zahtevkom 6 ali 7, označen s tem, da je R6 hidroksi na poziciji 5 indanovega obroča in R7 je hidroksi ali CpC^alkil ali C,-C4-hidroksialkil na poziciji 6 indanovega obroča, Rg pa je vodik.
- 11. Derivat v skladu z zahtevkom 1, označen s tem, da je n=m=1.
- 12. Derivat v skladu z zahtevkom 11, označen s tem, da so Rs do R„ vsi vodik.
- 13. Derivat v skladu z zahtevkom 11, označen s tem, da je R6 hidroksi skupina na poziciji 71,2,3,4-tetrahidronaftil obroča, R7 in R8 pa sta vodik.
- 14. Farmacevtsko sprejemljiv sestavek, ki vsebuje derivat, kot je definiran v kateremkoli od zahtevkov 1 do 13 in farmacevtsko sprejemljiv nosilec.
- 15. Derivat, kot je definiran v kateremkoli od zahtevkov 1 do 13, za uporabo pri postopku zdravljenja telesa ljudi ali živali.
- 16. Derivat, kot je definiran v kateremkoli od zahtevkov 1 do 13, za uporabo pri zdravljenju hipertenzije, glavkoma, kronične in akutne bolečine, migrene, driske, običajnega prehlada, ishemije, zasvojenosti s kemičnimi substancami, strahu, posebno predoperativnega strahu in različnih nevrolo{kih, mišično-kostnih, psihičnih in kognitivnih motenj ali kot dodatek ob anesteziji.
- 17. Uporaba derivata, kot je definiran v kateremkoli od zahtevkov 1 do 13, za izdelavo zdravila za uporabo pri zdravljenju hipertenzije, glavkoma, kronične in akutne bolečine, migrene, driske, običajnega prehlada, ishemije, zasvojenosti s kemičnimi substancami, strahu, posebno predoperativnega strahu in različnih nevroloških, mišično-kostnih, psihičnih in kognitivnih motenj.
- 18. Uporaba derivata, kot je definiran v kateremkoli od zahtevkov 1 do 13, pri izdelavi zdravila za uporabo kot dodatek ob anesteziji.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9520150.5A GB9520150D0 (en) | 1995-10-03 | 1995-10-03 | New imidazole derivatives |
| PCT/FI1996/000518 WO1997012874A1 (en) | 1995-10-03 | 1996-10-02 | Imidazole derivatives having affinity for alpha2 receptors activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI9620111A SI9620111A (sl) | 1998-10-31 |
| SI9620111B true SI9620111B (en) | 2001-12-31 |
Family
ID=10781676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9620111A SI9620111B (en) | 1995-10-03 | 1996-10-02 | Imidazole derivatives having affinity for alpha2 receptors activity |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6313311B1 (sl) |
| EP (1) | EP0888309B1 (sl) |
| JP (1) | JP4129891B2 (sl) |
| KR (1) | KR19990064013A (sl) |
| CN (1) | CN1068592C (sl) |
| AT (1) | ATE234819T1 (sl) |
| AU (1) | AU708002B2 (sl) |
| BG (1) | BG63916B1 (sl) |
| CA (1) | CA2231535C (sl) |
| CZ (1) | CZ291576B6 (sl) |
| DE (1) | DE69626862T2 (sl) |
| DK (1) | DK0888309T3 (sl) |
| EE (1) | EE04436B1 (sl) |
| ES (1) | ES2195013T3 (sl) |
| GB (1) | GB9520150D0 (sl) |
| HU (1) | HU224197B1 (sl) |
| IL (1) | IL123721A (sl) |
| LT (1) | LT4460B (sl) |
| LV (1) | LV12108B (sl) |
| NO (1) | NO311024B1 (sl) |
| NZ (1) | NZ319169A (sl) |
| PL (1) | PL189110B1 (sl) |
| PT (1) | PT888309E (sl) |
| RO (1) | RO120409B1 (sl) |
| RU (1) | RU2188194C2 (sl) |
| SI (1) | SI9620111B (sl) |
| SK (1) | SK283542B6 (sl) |
| UA (1) | UA49847C2 (sl) |
| WO (1) | WO1997012874A1 (sl) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA981080B (en) | 1997-02-11 | 1998-08-12 | Warner Lambert Co | Bicyclic inhibitors of protein farnesyl transferase |
| AU2002254265B2 (en) * | 1997-12-04 | 2008-05-15 | Allergan, Inc. | Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
| RU2235092C2 (ru) * | 1997-12-04 | 2004-08-27 | Оллерган Инк. | Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений |
| US6495584B1 (en) * | 1998-09-28 | 2002-12-17 | Orion Corporation | Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| WO2001000192A2 (en) * | 1999-06-25 | 2001-01-04 | Orion Corporation | Method of administering an imidazole derivative to obtain analgesia |
| CA2388979C (en) | 1999-10-29 | 2010-09-14 | Orion Corporation | Treatment or prevention of hypotension and shock with use of an imidazole derivative |
| US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
| FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
| PE20011321A1 (es) * | 2000-05-08 | 2002-01-03 | Orion Corp | Indanilimizadoles policiclicos nuevos con actividad adrenergica alfa 2 |
| TW200930291A (en) * | 2002-04-29 | 2009-07-16 | Bayer Cropscience Ag | Pesticidal heterocycles |
| FR2839719B1 (fr) * | 2002-05-16 | 2004-08-06 | Pf Medicament | Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments |
| FI20022159A0 (fi) * | 2002-12-05 | 2002-12-05 | Orion Corp | Uusia farmaseuttisia yhdisteitä |
| FI116292B (fi) * | 2003-01-08 | 2005-10-31 | Juvantia Pharma Ltd Oy | Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita |
| DE102004035322A1 (de) * | 2004-07-21 | 2006-02-16 | Universität des Saarlandes | Selektive Hemmstoffe humaner Corticoidsynthasen |
| KR20080039982A (ko) | 2005-08-25 | 2008-05-07 | 쉐링 코포레이션 | 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체 |
| US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
| JP2009506051A (ja) | 2005-08-25 | 2009-02-12 | シェーリング コーポレイション | α２Ｃアドレナリン受容体アゴニスト |
| EP1981499A1 (en) * | 2006-01-27 | 2008-10-22 | F.Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of cns disorders |
| ES2381589T3 (es) | 2006-10-19 | 2012-05-29 | F. Hoffmann-La Roche Ag | Aminometil-4-imidazoles |
| CN101535292A (zh) | 2006-11-02 | 2009-09-16 | 弗·哈夫曼-拉罗切有限公司 | 作为痕量胺相关受体的调节剂的取代的2-咪唑类化合物 |
| KR101134226B1 (ko) * | 2006-11-16 | 2012-04-10 | 에프. 호프만-라 로슈 아게 | 치환된 4-이미다졸 |
| ATE509628T1 (de) | 2006-12-13 | 2011-06-15 | Hoffmann La Roche | Neue 2-imidazole als liganden für trace amine associated receptors (taar) |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| EP2114906B1 (en) | 2007-02-02 | 2014-08-06 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands for cns disorders |
| EP2398776A1 (en) | 2007-02-13 | 2011-12-28 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
| MX2009008777A (es) | 2007-02-13 | 2009-08-25 | Schering Corp | Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
| JP2010518159A (ja) | 2007-02-13 | 2010-05-27 | シェーリング コーポレイション | 機能選択性α２Ｃアドレナリン受容体アゴニスト |
| CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
| WO2009003868A2 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| MX2009013745A (es) | 2007-07-03 | 2010-01-26 | Hoffmann La Roche | 4-imidazolinas y su uso como antidepresivos. |
| BRPI0813837A2 (pt) | 2007-07-27 | 2015-01-06 | Hoffmann La Roche | 2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar |
| CN101784515A (zh) | 2007-08-03 | 2010-07-21 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物 |
| US8383818B2 (en) | 2008-02-21 | 2013-02-26 | Merck Sharp & Dohme Corp. | Functionally selective alpha2C adrenoreceptor agonists |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| US8324213B2 (en) | 2008-10-07 | 2012-12-04 | Merck Sharp & Dohme Corp. | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators |
| US20110021588A1 (en) | 2009-05-15 | 2011-01-27 | Recro Pharma, Inc. | Sublingual dexmeditomidine compositions and methods of use thereof |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US8673950B2 (en) | 2010-11-02 | 2014-03-18 | Hoffmann-Laroche Inc. | Dihydrooxazol-2-amine derivatives |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| EP2787970B1 (en) | 2011-12-11 | 2018-04-11 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| KR101631003B1 (ko) * | 2012-01-12 | 2016-06-15 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(taar)로서 헤테로환형 유도체 |
| HK1206720A1 (en) | 2012-09-14 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease |
| CA2879176C (en) * | 2012-09-17 | 2020-10-27 | F.Hoffmann-La Roche Ag | Triazole carboxamide derivatives |
| WO2015165085A1 (en) | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| WO2016030306A1 (en) | 2014-08-27 | 2016-03-03 | F. Hoffmann-La Roche Ag | Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders |
| CA2954098A1 (en) | 2014-08-27 | 2016-03-03 | F. Hoffmann-La Roche Ag | Substituted azetidine derivatives as taar ligands |
| CR20180443A (es) | 2016-03-17 | 2018-11-21 | Hoffmann La Roche | Derivado de morfolina |
| CN116496261B (zh) * | 2023-03-09 | 2025-06-27 | 中国人民解放军军事科学院军事医学研究院 | 4-(1h)-咪唑类衍生物及其医药用途 |
| CN118684628B (zh) * | 2024-05-20 | 2025-06-17 | 中国人民解放军军事科学院军事医学研究院 | 取代二氢茚基咪唑类化合物及其制备方法和用途 |
| CN119424420B (zh) * | 2024-11-15 | 2025-11-21 | 中国人民解放军军事科学院军事医学研究院 | 取代二氢茚基咪唑类化合物的抗肿瘤用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3636002A (en) * | 1969-12-15 | 1972-01-18 | Janssen Pharmaceutica Nv | 1-(2-halobenzyloxy-1-indanyl)-imidazoles |
| ES523609A0 (es) * | 1982-07-05 | 1985-03-01 | Erba Farmitalia | Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos. |
| US4634705A (en) * | 1984-06-06 | 1987-01-06 | Abbott Laboratories | Adrenergic amidines |
| US4659730A (en) * | 1984-06-18 | 1987-04-21 | Eli Lilly And Company | Aromatase inhibiting imidazole derivatives |
| GB2167408B (en) * | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| FI81092C (fi) * | 1986-05-15 | 1990-09-10 | Farmos Oy | Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat. |
| US4878940A (en) * | 1987-04-02 | 1989-11-07 | Janssen Pharmaceutica N.V. | Herbicidal 1,5-substituted 1H-imidazoles |
| IL91542A0 (en) * | 1988-10-06 | 1990-04-29 | Erba Carlo Spa | N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them |
| GB2225782A (en) * | 1988-12-09 | 1990-06-13 | Farmos Group Limited | Imidazole derivatives useful for treatment of diabetes |
| GB9127050D0 (en) * | 1991-12-20 | 1992-02-19 | Orion Yhtymae Oy | Substituted imidazole derivatives and their preparation and use |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| US6388090B2 (en) * | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
-
1995
- 1995-10-03 GB GBGB9520150.5A patent/GB9520150D0/en active Pending
-
1996
- 1996-10-02 JP JP51399497A patent/JP4129891B2/ja not_active Expired - Lifetime
- 1996-10-02 CZ CZ19981018A patent/CZ291576B6/cs not_active IP Right Cessation
- 1996-10-02 AT AT96932609T patent/ATE234819T1/de active
- 1996-10-02 CA CA002231535A patent/CA2231535C/en not_active Expired - Lifetime
- 1996-10-02 HU HU9802927A patent/HU224197B1/hu active IP Right Grant
- 1996-10-02 KR KR1019980702490A patent/KR19990064013A/ko not_active Ceased
- 1996-10-02 DE DE69626862T patent/DE69626862T2/de not_active Expired - Lifetime
- 1996-10-02 RO RO98-00825A patent/RO120409B1/ro unknown
- 1996-10-02 EP EP96932609A patent/EP0888309B1/en not_active Expired - Lifetime
- 1996-10-02 SI SI9620111A patent/SI9620111B/sl unknown
- 1996-10-02 SK SK439-98A patent/SK283542B6/sk not_active IP Right Cessation
- 1996-10-02 PL PL96328167A patent/PL189110B1/pl unknown
- 1996-10-02 RU RU98108027/04A patent/RU2188194C2/ru active
- 1996-10-02 UA UA98031588A patent/UA49847C2/uk unknown
- 1996-10-02 ES ES96932609T patent/ES2195013T3/es not_active Expired - Lifetime
- 1996-10-02 US US09/051,151 patent/US6313311B1/en not_active Expired - Lifetime
- 1996-10-02 EE EE9800101A patent/EE04436B1/xx unknown
- 1996-10-02 DK DK96932609T patent/DK0888309T3/da active
- 1996-10-02 IL IL12372196A patent/IL123721A/en not_active IP Right Cessation
- 1996-10-02 NZ NZ319169A patent/NZ319169A/xx not_active IP Right Cessation
- 1996-10-02 AU AU71327/96A patent/AU708002B2/en not_active Expired
- 1996-10-02 WO PCT/FI1996/000518 patent/WO1997012874A1/en not_active Ceased
- 1996-10-02 CN CN96197438A patent/CN1068592C/zh not_active Expired - Lifetime
- 1996-10-02 PT PT96932609T patent/PT888309E/pt unknown
-
1998
- 1998-03-12 BG BG102324A patent/BG63916B1/bg unknown
- 1998-03-31 LV LVP-98-61A patent/LV12108B/en unknown
- 1998-04-02 NO NO19981496A patent/NO311024B1/no not_active IP Right Cessation
- 1998-04-22 LT LT98-057A patent/LT4460B/lt not_active IP Right Cessation
-
2001
- 2001-07-16 US US09/904,836 patent/US6479530B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9620111B (en) | Imidazole derivatives having affinity for alpha2 receptors activity | |
| GEP19991870B (en) | Alkyl Amine Derivatives of Substituted Quinoxaline 2,3-Diones as Glutamate Receptor Antagonists | |
| ES2141137T3 (es) | Agentes terapeuticos para la enfermedad de parkinson. | |
| RU98108027A (ru) | Производные имидазола, обладающие аффинностью в отношении активности альфа2- рецепторов | |
| ATE294796T1 (de) | Chinazolin derivate | |
| MY132405A (en) | Quinazoline derivatives | |
| BRPI0017548A2 (pt) | Composto, e, processo para a preparação de um composto | |
| UY25805A1 (es) | Azalidas de 13 miembros y su uso como agentes antibióticos. | |
| IL134894A (en) | 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them | |
| GEP19991869B (en) | Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists | |
| PT1082116E (pt) | Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento | |
| FI974609A0 (fi) | Uusia heterosyklisiä yhdisteitä kivun hoitoon ja niiden käyttö | |
| ES2141134T3 (es) | Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares. | |
| ATE83484T1 (de) | 20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen. | |
| KR970704686A (ko) | 비시클로락탐 화합물, 그 용도 및 그 제조중간체(bicyclolactam compounds, use of the same and intermediate in the production of the same) | |
| JO1815B1 (en) | Therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date |